Stock PCVX VAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq
Other stock markets
 21:00:00 20/06/2024 BST 		5-day change 1st Jan Change
72.76 USD +0.71% Intraday chart for Vaxcyte, Inc. -1.69% +15.86%
05-22 Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing MT
05-14 Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing
MT
Transcript : Vaxcyte, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
GL
Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing
MT
Vaxcyte Insider Sold Shares Worth $490,199, According to a Recent SEC Filing
MT
Vaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
GL
Certain Pre-Funded Warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.
CI
Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.
CI
Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2024.
CI
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing
MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating
MT
Transcript : Vaxcyte, Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:40 AM
Transcript : Vaxcyte, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
GL
Vaxcyte, Inc. Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
CI
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating
MT
Vaxcyte Q4 Loss Widens
MT
Transcript : Vaxcyte, Inc., Q4 2023 Earnings Call, Feb 27, 2024
Vaxcyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. News Vaxcyte, Inc.